Reported 1 day ago
Alnylam Pharmaceuticals has received expanded US approval for its heart drug, Amvuttra, aimed at treating transthyretin amyloid cardiomyopathy (ATTR-CM), allowing it to compete against Pfizer’s established products. While Amvuttra presents a promising treatment option with claims extending beyond its competitors, including a focus on urgent heart failure, its high price and the need for injections every three months pose challenges against Pfizer’s more affordable and convenient oral medications. Analysts predict significant market potential for Alnylam, yet its ability to unseat Pfizer remains uncertain.
Source: YAHOO